Compare Johnson & Johnson (JNJ) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs NEOS S&P 500 High Income ETF — how do they compare? Johnson & Johnson trades at $248.08 (market cap $598.96B), while NEOS S&P 500 High Income ETF trades at $53.25. The key difference: Johnson & Johnson pays a 2.15% dividend while NEOS S&P 500 High Income ETF pays none. Which is the better fit depends on your goals.
| JNJ | SPYI | |
|---|---|---|
Market Cap | $598.96B | — |
Volume | 6,156,228 | — |
Sector | Health | Income / Options Overlay |
52-Week High | $267.24 | $54.07 |
52-Week Low | $164.36 | $47.98 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
SPYI, the NEOS S&P 500 High Income ETF, trades at $53.01, down 0.11% on the day. The technical outlook is bearish based on moving averages, with neutral oscillators. The fund has surpassed $10 billion in assets under management and delivers consistent monthly distributions, with a yield around 12%. Recent news highlights its appeal for income-focused investors seeking S&P 500 exposure with lower volatility.
The outlook for SPYI is supported by strong investor demand for high-yield income solutions, though the bearish technical signal and reliance on options strategies present risks. The fund's ability to generate income without significant NAV erosion remains a key advantage in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
